Stryker Corporation Common Stock (SYK)
Stock · NYSE · Health Care
$294.69as of 10/16/2026
Price chart
Active signals
SYK Signal Track Record
How signals performed across all stocks →What SYK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +1.5% | 57% | September 18, 2026 |
| Bollinger Band BreakoutActive now | 25 | +1.4% | 68% | October 5, 2026 |
| Bollinger Band Breakdown | 21 | -1.7% | 48% | September 2, 2026 |
| 200-Day Moving Average TouchActive now | 18 | +0.4% | 50% | August 7, 2026 |
| Any 20-session window (baseline) | +0.9% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SYK
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care di…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 56,000
- Website
- www.stryker.com/
Fundamentals
- 1-day range
- $293.77$299.67
- Market cap
- $129.43B
- P/E (trailing)
- 29.93
- P/E (forward)
- 17.66
- EPS (trailing)
- $9.65
- Dividend yield
- 1.02%
- Beta
- 0.79
- Avg. volume
- 2.59M
- Ex-dividend date
- September 30, 2026
- Dividend pay date
- October 30, 2026
How Stryker Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 11, 2026 · via SEC EDGAR / Finnhub
Forecasts
26 analyst ratings
Stryker Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- SYKStryker Corporation Common Stock$294.66▲ 0.49%Market cap $129.43BP/E 29.93$267$392.55
- MMM3M Company Common Stock$164.75▼ 0.35%Market cap $93.20BP/E 28.58$139.34$184.9
- BSXBoston Scientific Corporation Common Stock$44.39▲ 0.57%Market cap $71.45BP/E 17.32$41.39$105.65
- BDXBecton Dickinson and Company Common Stock$191.75▼ 1.04%Market cap $48.79BP/E 54.13$127.59$193.07
- MDLNMedline Inc. Class A Common Stock$35.96▼ 1.67%Market cap $45.34BP/E 69.38$31.49$50.88
- RMDResMed Inc. Common Stock$238.97▼ 1.35%Market cap $32.38BP/E 22.23$180.27$277.67
- DXCMDexCom Inc. Common Stock$86.04▼ 1.90%Market cap $31.33BP/E 32.73$54.11$92.59
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SYK Stryker Corporation Common Stock | $129.43B | 29.93 | $294.66 | ▲ 0.49% | $267$392.55 |
| MMM 3M Company Common Stock | $93.20B | 28.58 | $164.75 | ▼ 0.35% | $139.34$184.9 |
| BSX Boston Scientific Corporation Common Stock | $71.45B | 17.32 | $44.39 | ▲ 0.57% | $41.39$105.65 |
| BDX Becton Dickinson and Company Common Stock | $48.79B | 54.13 | $191.75 | ▼ 1.04% | $127.59$193.07 |
| MDLN Medline Inc. Class A Common Stock | $45.34B | 69.38 | $35.96 | ▼ 1.67% | $31.49$50.88 |
| RMD ResMed Inc. Common Stock | $32.38B | 22.23 | $238.97 | ▼ 1.35% | $180.27$277.67 |
| DXCM DexCom Inc. Common Stock | $31.33B | 32.73 | $86.04 | ▼ 1.90% | $54.11$92.59 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stryker Makes $400 Million Robotic Surgery Betbenzinga · 10/13/2026
- Stryker (SYK) Is Changing CEOs After the Stock Fell 25% Over Twelve MonthsYahoo · 10/9/2026
- Stryker (SYK): Near-Term Growth Concerns Overshadow Long-Term StrengthYahoo · 10/9/2026
- 1 S&P 500 Stock with Solid Fundamentals and 2 We Turn DownYahoo · 10/9/2026
- 1 Profitable Stock on Our Watchlist and 2 We IgnoreYahoo · 10/8/2026
- The Monopolistic Razor-and-Blade Engine I Can’t Stop BuyingYahoo · 10/8/2026
- Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Misses Revenue EstimatesYahoo · 10/8/2026
- Stryker (NYSE:SYK) Balances Dividend Quality and Profitability for Income InvestorsChartMill · 10/8/2026
- Stryker (SYK) Stock Could Be Cheap After Its 26% SlideYahoo · 10/8/2026
Insider Activity
Insider Actions →- Preston Wendell Wells · September 24, 2026 · J109
- Preston Wendell Wells · September 22, 2026 · J962
- Dylan Bram Crotty · August 21, 2026 · Sale441 @ $328.61
- Ronda E. Stryker · August 19, 2026 · Sale805 @ $343.47
- Ronda E. Stryker · August 19, 2026 · Sale3.9K @ $342.8
- Ronda E. Stryker · August 19, 2026 · Sale3.3K @ $341.84
- Ronda E. Stryker · August 19, 2026 · Sale16.6K @ $340.71
- Ronda E. Stryker · August 19, 2026 · Sale10.8K @ $339.71
- Ronda E. Stryker · August 19, 2026 · Sale11.3K @ $338.9
- Ronda E. Stryker · August 19, 2026 · Sale2.3K @ $337.98
- Ronda E. Stryker · August 19, 2026 · Sale320 @ $336.79
- Ronda E. Stryker · August 19, 2026 · Sale80 @ $335.06
- Ronda E. Stryker · August 19, 2026 · Sale200 @ $333.93
- Ronda E. Stryker · August 19, 2026 · Sale440 @ $333.18
- Ronda E. Stryker · August 19, 2026 · Sale40 @ $331.81
Institutional Ownership
March 31, 2026
- Total shares held
- 272.96M
- Total value held
- $84.00B
- Institutional holders
- 2272
- Unknown27.60M
- Unknown22.38M
- Unknown15.94M
- Unknown15.35M
- Unknown10.04M
- Unknown8.12M
- Unknown7.75M
- Unknown6.30M
- Unknown6.05M
- Unknown5.61M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3
Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3. Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.